Hydrophobic Interaction Chromatography Market Outlook:
Hydrophobic Interaction Chromatography Market size was over USD 479.9 million in 2025 and is estimated to reach USD 912.4 million by the end of 2035, expanding at a CAGR of 7.4% during the forecast timeline, i.e., 2026-2035. In 2026, the industry size of hydrophobic interaction chromatography is assessed at USD 515.4 million by the end of 2026.
The growing demand for biologic drugs to develop targeted therapies for treating chronic illnesses, including cancer, autoimmune disorders, and rare genetic conditions, is creating a surge in the market. This demography can be testified by the NLM’s conclusion on worldwide chronic disease expenses, which is predicted to total $47 trillion by 2030. Besides, the number of new cancer cases is expected to surpass 35 million by 2050, underscoring a 77% increase from 2022, as per the WHO report. Another study from February 2025 calculated the prevalence of rare diseases around the globe to range between 263 million and 446 million.
The growing economic burden on patients and healthcare systems from the elongated and expensive treatments of these ailments is pushing respective governments to cultivate cost-effective solutions from biomedical processing. Hence, the volume of both the consumer base and capital influx is amplifying in the market. However, the lack of an adequate supply chain for the required raw materials and inflation in the cost of equipment are collectively prohibiting companies from offering comprehensive payers’ pricing in this sector. Testifying to the same, a 2022 NLM study revealed that downstream purification accounts for 50-80% of the entire production cost of biopharmaceuticals.
